Related references
Note: Only part of the references are listed.Arsenic trioxide for refractory aplastic anemia
Quande Lin et al.
ANNALS OF HEMATOLOGY (2013)
Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide
Miran Jang et al.
CANCER RESEARCH (2012)
Cancer incidence and pattern of arsenic concentration in drinking water wells in Cordoba, Argentina
Laura Rosana Aballay et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL HEALTH RESEARCH (2012)
Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines
M. Stepnik et al.
MEDICAL ONCOLOGY (2012)
Revisiting the differentiation paradigm in acute promyelocytic leukemia
Julien Ablain et al.
BLOOD (2011)
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study
Wing-Yan Au et al.
BLOOD (2011)
Phase 1 Study of Arsenic Trioxide, High-Dose Cytarabine, and Idarubicin to Down-Regulate Constitutive Signal Transducer and Activator of Transcription 3 Activity in Patients Aged < 60 Years With Acute Myeloid Leukemia
Meir Wetzler et al.
CANCER (2011)
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells
Ubaldo E. Martinez-Outschoorn et al.
CANCER BIOLOGY & THERAPY (2011)
Exploring Old Drugs for the Treatment of Hematological Malignancies
F. Gan et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix metalloproteinase-2 pathway
Yingxia Liu et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2011)
Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia
Ardeshir Ghavamzadeh et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Targeting SP1 Transcription Factor in Prostate Cancer Therapy
Umesh T. Sankpal et al.
Medicinal Chemistry (2011)
Arsenic, Stem Cells, and the Developmental Basis of Adult Cancer
Erik J. Tokar et al.
TOXICOLOGICAL SCIENCES (2011)
Involvement of Glycogen Synthase Kinase-3β in Arsenic Trioxide-Induced p21 Expression
Huei-Sheng Huang et al.
TOXICOLOGICAL SCIENCES (2011)
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
Bayard L. Powell et al.
BLOOD (2010)
The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel
Qian Liu et al.
BMC MEDICAL GENOMICS (2010)
Development of target-specific treatments in multiple myeloma
Asher A. Chanan-Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Activation of the p38 MAPK/Akt/ERK1/2 Signal Pathways Is Required for the Protein Stabilization if CDC6 and Cyclin D1 in Low-Dose Arsenite-Induced Cell Proliferation
Youhong Liu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia
Steven D. Gore et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data
Vikram Mathews et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition
Jianguo Wen et al.
LEUKEMIA RESEARCH (2010)
Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector
Jynho Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Arsenic trioxide promotes mitochondrial DNA mutation and cell apoptosis in primary APL cells and NB4 cell line
Meng Ran et al.
SCIENCE CHINA-LIFE SCIENCES (2010)
Interspecies differences in metabolism of arsenic by cultured primary hepatocytes
Zuzana Drobna et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
The hedgehog pathway as a therapeutic target for treatment of breast cancer
M. F. Barginear et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Notoriety to respectability: a short history of arsenic prior to its present day use in haematology
Derek Doyle
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Levels of urinary total and speciated arsenic in the US population: National Health and Nutrition Examination Survey 2003-2004
Kathleen L. Caldwell et al.
JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY (2009)
Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells
Helen M. Pettersson et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Arsenic metabolism is influenced by polymorphisms in genes involved in one-carbon metabolism and reduction reactions
Karin Schlawicke Engstrom et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2009)
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia
Jiong Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Ethnic differences in five intronic polymorphisms associated with arsenic metabolism within human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene
Junko Fujihara et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2009)
Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells
Vichaya Charoensuk et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2009)
New drugs in multiple myeloma
James R Berenson et al.
Current Opinion in Supportive and Palliative Care (2009)
Analytical artefacts in the speciation of arsenic in clinical samples
Zdenka Slejkovec et al.
ANALYTICA CHIMICA ACTA (2008)
Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Xing Cui et al.
CURRENT MEDICINAL CHEMISTRY (2008)
From the desk of the guest editor
Sujit Ranjan Sengupta
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2008)
Arsenicosis: Diagnosis and treatment
Nilay Kanti Das et al.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2008)
Arsenic exposure and prevalence of type 2 diabetes in US adults
Ana Navas-Acien et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Speciation analysis of arsenic in biological matrices by automated hydride generation-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer)
Araceli Hernandez-Zavala et al.
JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY (2008)
Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2
Francois Binet et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13
Olaf Merkel et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2008)
Mineral arsenicals in traditional medicines: Orpiment, realgar, and arsenolite
Jie Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Arsenic trioxide decreases AKT protein in a caspase-dependent manner
Koren K. Mann et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Arsenic trioxide mechanisms of action - looking beyond acute promyelocytic leukemia
Dennis A. Carney
LEUKEMIA & LYMPHOMA (2008)
Arsenic trioxide mutational spectrum analysis in the mouse lymphoma assay
Carolina Soriano et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile
Alba Hernandez et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Toxicogenomics of arsenic: Classical ideas and recent advances
Pritha Ghosh et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2008)
Genetic variations associated with interindividual sensitivity in the response to arsenic exposure
Alba Hernandez et al.
PHARMACOGENOMICS (2008)
Arsenic trioxide phosphorylates c-Fos to transactivate p21WAF1/CIP1 expression
Zi-Miao Liu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2008)
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
Chia-Chi Lin et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
Gene-mutation induction by arsenic compounds in the mouse lymphoma assay
Carolina Soriano et al.
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS (2007)
New data with arsenic trioxide in leukemias and myelodysplastic syndromes
Mikkael A. Sekeres
CLINICAL LYMPHOMA & MYELOMA (2007)
Arsenic-induced alteration in the expression of genes related to type 2 diabetes mellitus
Andrea Diaz-Villasenor et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2007)
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia
Alberto Catalano et al.
BLOOD (2007)
Novel therapies in myeloma
Patrick J. Hayden et al.
CURRENT OPINION IN HEMATOLOGY (2007)
Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity
Z. Diaz et al.
LEUKEMIA (2007)
The diabetogenic effects of the combination of humic acid and arsenic: In vitro and in vivo studies
Cheng-Chieh Yen et al.
TOXICOLOGY LETTERS (2007)
Thio-dimethylarsinate is a common metabolite in urine samples from arsenic-exposed women in Bangladesh
Reingard Raml et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2007)
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid
Richard A. Campbell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico
Jose Antonio Coronado-Gonzalez et al.
ENVIRONMENTAL RESEARCH (2007)
MW-year study of lung and bladder canceir mortality in Chile related to arsenic in drinking water
Guillermo Marshall et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Gender differences in the disposition and toxicity of metals
Marie Vahter et al.
ENVIRONMENTAL RESEARCH (2007)
Arsenic trioxide in hematological malignancies: The new discovery of an ancient drug
A. Bonati et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2006)
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study
James R. Berenson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Real-time PCR analysis of PML-RARα in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy
S. H. Ghaffari et al.
ANNALS OF ONCOLOGY (2006)
Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications
E. Agostinelli et al.
AMINO ACIDS (2006)
Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid
Jing-jing Li et al.
ACTA PHARMACOLOGICA SINICA (2006)
Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice
Bing Liu et al.
CANCER SCIENCE (2006)
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes
Gary J. Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Arsenic exposure and type 2 diabetes: A systematic review of the experimental and epidemiologic evidence
A Navas-Acien et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2006)
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity
V Mathews et al.
BLOOD (2006)
Methylated arsenicals: The implications of metabolism and carcinogenicity studies in rodents to human risk assessment
SM Cohen et al.
CRITICAL REVIEWS IN TOXICOLOGY (2006)
Cytogenetic evaluation of arsenic trioxide toxicity in Sprague-Dawley rats
AK Patlolla et al.
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS (2005)
Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan
CH Tseng et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2005)
Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic
OL Valenzuela et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2005)
Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent
S Amadori et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective
CJ Lin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma
MA Hussein et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Channelling the Emperor: what really killed Napoleon?
F Mari et al.
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2004)
The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds
S Hirano et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2004)
Glutathione modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of trimethylarsine oxide and trimethylarsine
SB Waters et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2004)
Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment
ZW Wang et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2004)
Acute and chronic arsenic toxicity
RN Ratnaike
POSTGRADUATE MEDICAL JOURNAL (2003)
Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia
WY Au et al.
BLOOD (2003)
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia
E Raffoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Arsenic trioxide: Acute promyelocytic leukemia and beyond
T Bachleitner-Hofmann et al.
LEUKEMIA & LYMPHOMA (2002)
Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects
G Baj et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report
DP Lu et al.
BLOOD (2002)
Arsenic trioxide in multiple myeloma: Rationale and future directions
KC Anderson et al.
CANCER JOURNAL (2002)
The cellular metabolism and systemic toxicity of arsenic
DJ Thomas et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2001)
Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage
Y Shen et al.
LEUKEMIA (2001)
Recent advances in arsenic carcinogenesis: Modes of action, animal model systems, and methylated arsenic metabolites
KT Kitchin
TOXICOLOGY AND APPLIED PHARMACOLOGY (2001)
Methylated trivalent arsenic species are genotoxic
MJ Mass et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2001)
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide
D Unnikrishnan et al.
BLOOD (2001)
History of the development of arsenic derivatives in cancer therapy
S Waxman et al.
ONCOLOGIST (2001)
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia
K Ohnishi et al.
ANNALS OF INTERNAL MEDICINE (2000)
Speciation of key arsenic metabolic intermediates in human urine
XC Le et al.
ANALYTICAL CHEMISTRY (2000)
Share Paper
